Kieger Impact Healthcare Fund Class A CHF (H) Accumulating

Reference Data

ISIN LU2207278404
Valor Number 120730677
Bloomberg Global ID
Fund Name Kieger Impact Healthcare Fund Class A CHF (H) Accumulating
Fund Provider Kieger AG Kieger AG
Limmatstrasse 264, CH-8005 Zürich
Phone: +41 44 444 18 44
Web: https://kieger.com/
E-Mail: info@kieger.com
Fund Provider Kieger AG
Representative in Switzerland ACOLIN Fund Services AG
Zürich
Phone: +41 44 396 96 96
Distributor(s)
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved.
Peculiarities

Fund Prices

Current Price * 76.94 CHF 16.04.2025
Previous Price * 77.77 CHF 15.04.2025
52 Week High * 92.13 CHF 15.05.2024
52 Week Low * 74.15 CHF 08.04.2025
NAV * 76.94 CHF 16.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 65,445,794
Unit/Share Assets *** 6,116,391
Trading Information SIX

Performance

YTD Performance -3.93% 31.12.2024
16.04.2025
1 month -6.16% 17.03.2025
16.04.2025
3 months -8.75% 16.01.2025
16.04.2025
6 months -10.80% 16.10.2024
16.04.2025
1 year -9.31% 16.04.2024
16.04.2025
2 years -24.25% 17.04.2023
16.04.2025
3 years -23.06% 31.08.2022
16.04.2025
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Intra-Cellular Therapies Inc 4.79%
Hikma Pharmaceuticals PLC 3.88%
Ambu AS Class B 3.86%
DexCom Inc 3.73%
Abbott Laboratories 3.73%
Sandoz Group AG Registered Shares 3.63%
Penumbra Inc 3.60%
Amplifon SpA Az nom Post Frazionamento 3.56%
Revvity Inc 3.54%
Demant AS 3.53%
Last data update 31.01.2025

Cost / Risk

TER *** 1.27%
TER date *** 30.09.2023
Performance Fee ***
PTR
Max. Management Fee *** 1.00%
Ongoing Charges *** 1.27%
SRRI ***
SRRI date *** 30.09.2022

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)